These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 32643174

  • 1. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.
    Olszewska B, Żawrocki A, Lakomy J, Karczewska J, Gleń J, Zabłotna M, Malek M, Jankau J, Lange M, Biernat W, Nowicki RJ, Sokołowska-Wojdyło M.
    Int J Dermatol; 2020 Sep; 59(9):1106-1112. PubMed ID: 32643174
    [Abstract] [Full Text] [Related]

  • 2. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
    Pérez C, Mondéjar R, García-Díaz N, Cereceda L, León A, Montes S, Durán Vian C, Pérez Paredes MG, González-Morán A, Alegre de Miguel V, Sanz Anquela JM, Frias J, Limeres MA, González LM, Martín Dávila F, Beltrán M, Mollejo M, Méndez JR, González MA, González García J, López R, Gómez A, Izquierdo F, Ramos R, Camacho C, Rodriguez-Pinilla SM, Martínez N, Vaqué JP, Ortiz-Romero PL, Piris MA.
    Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
    [Abstract] [Full Text] [Related]

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [Abstract] [Full Text] [Related]

  • 4. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
    Luna DE, Shinohara MM.
    Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
    [Abstract] [Full Text] [Related]

  • 5. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S, Black RA, Nagao M, Sepassi M, Sharma G, Thornton S, Kim YH, Braverman J.
    J Med Internet Res; 2019 Jan 07; 21(1):e11302. PubMed ID: 30617041
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K, Jonak C, Woei-A-Jin FJSH, Guenova E, Busschots AM, Bervoets A, Hauben E, Knobler R, Porkert S, Fassnacht C, Cowan R, Papadavid E, Beylot-Barry M, Berti E, Alberti Violetti S, Estrach T, Matin R, Akilov O, Vakeva L, Prince M, Bates A, Bayne M, Wachsmuch R, Wehkamp U, Marschalko M, Servitje O, Turner D, Weatherhead S, Wobser M, Sanches JA, McKay P, Klemke D, Peng C, Howles A, Yoo J, Evison F, Scarisbrick J.
    Br J Dermatol; 2020 Mar 07; 182(3):770-779. PubMed ID: 31049926
    [Abstract] [Full Text] [Related]

  • 10. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
    Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M.
    Cell Cycle; 2014 Mar 07; 13(21):3331-5. PubMed ID: 25485578
    [Abstract] [Full Text] [Related]

  • 11. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y, Stoll JR, Moskowitz A, Pulitzer M, Horwitz S, Myskowski P, Noor SJ.
    J Am Acad Dermatol; 2021 Nov 07; 85(5):1093-1106. PubMed ID: 33945836
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.
    Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD.
    J Eur Acad Dermatol Venereol; 2021 Dec 07; 35(12):2377-2387. PubMed ID: 34331819
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
    Parker SR, Bethaney JV.
    G Ital Dermatol Venereol; 2009 Aug 07; 144(4):467-85. PubMed ID: 19755952
    [Abstract] [Full Text] [Related]

  • 17. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
    Shareef MM, Elgarhy LH, Wasfy Rel-S.
    Asian Pac J Cancer Prev; 2015 Aug 07; 16(13):5359-64. PubMed ID: 26225678
    [Abstract] [Full Text] [Related]

  • 18. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
    Quadri I, Reneau JC, Hanel W, Chung CG.
    Front Immunol; 2023 Aug 07; 14():1291259. PubMed ID: 38022633
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Leroy S, Dubois S, Tenaud I, Chebassier N, Godard A, Jacques Y, Dréno B.
    Br J Dermatol; 2001 May 07; 144(5):1016-23. PubMed ID: 11359391
    [Abstract] [Full Text] [Related]

  • 20. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Jarrousse V, Quereux G, Marques-Briand S, Knol AC, Khammari A, Dreno B.
    Eur J Dermatol; 2006 May 07; 16(6):636-41. PubMed ID: 17229603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.